Recently, it has been demonstrated that in B-ALL, distinct developmental states are associated with genomic alterations and clinical characteristics. Patients with DUX4 mutation-positive B-cell ...

1 School of Life and Health Sciences, Hubei University of Technology, Wuhan, China 2 Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, Guangzhou, China Embryonic stem cells ...

Of the 70 patients identified in the study who were DUX4-positive, only 7.1% (n=5) of patients experienced a relapse while being treated according to the medium-risk or high-risk protocols of their ...

Delpacibart braxlosiran (AOC 1020), the first investigational therapy to target the underlying cause of FSHD, provided greater than 50% mean reduction across multiple DUX4 regulated gene panels (2 ...

Dyne Therapeutics has patented a complex involving a muscle-targeting agent linked to a molecular payload that inhibits DUX4 expression. The patent includes an anti-TfR antibody covalently linked to ...

plays an important role to activate the downstream genes of DUX. However, how MERVLs functions during ZGA remains mysterious. Here we investigated two important aspects of MERVLs regulation, the ...

a. (Left) Mouse DUX aligned to itself, revealing five repeats. (Right) Diagram of mouse DUX and human DUX4. b. Amino acid alignment of mouse DUX C-terminal repeats and comparison to human DUX4. A 14 ...

Arrowhead Therapeutics has asked for permission to launch a clinical trial of ARO-DUX4, an experimental RNA-based medicine for facioscapulohumeral muscular dystrophy (FSHD) type 1, in New Zealand. The ...

PASADENA, Calif.--(BUSINESS WIRE)--$arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to initiate a ...

But first, let’s take a step back. DUX4 is one member of a family of DoUble homeoboX (DUX) transcription factors which are uniquely expressed in placental mammals. Its canonical function is to ...